Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beyondspring ( (BYSI) ) has shared an announcement.
On September 22, 2025, SEED Therapeutics completed the second close of its $30 million Series A-3 financing, selling additional Series A-3 Preferred Shares for $6 million. This financing, along with FDA clearance of its IND application for its lead program targeting RBM39, marks SEED’s transition into a clinical-stage company. The company plans to start first-in-human clinical trials of ST-01156 in Q1 2026, with strong financial backing from partners like Eli Lilly and Eisai, supporting its strategy to advance its innovative therapies.
Spark’s Take on BYSI Stock
According to Spark, TipRanks’ AI Analyst, BYSI is a Neutral.
Beyondspring’s overall stock score reflects its significant financial challenges, with zero revenue and negative margins indicating severe financial distress. While technical analysis shows some positive short-term momentum, the stock is nearing overbought conditions. The negative P/E ratio highlights overvaluation concerns, significantly impacting the overall score.
To see Spark’s full report on BYSI stock, click here.
More about Beyondspring
SEED Therapeutics is a clinical-stage biotechnology company that focuses on pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Utilizing its proprietary RITE3 platform, SEED targets protein degradation with small-molecule precision, with a pipeline spanning oncology, neurodegeneration, immunology, and virology.
Average Trading Volume: 29,357
Technical Sentiment Signal: Strong Sell
Current Market Cap: $72.19M
See more insights into BYSI stock on TipRanks’ Stock Analysis page.